IP Library Granted Patent US 11,638,707
Granted Patent B2
US 11,638,707 · App. 16/929,893 · Granted May 2, 2023

Substituted amino triazoles useful as chitinase inhibitors

Inventors: Marzena Mazur (Lodz, PL); Gleb Andryianau (Warsaw, PL); Lukasz Joachimiak (Lodz, PL); Wojciech Czestkowski (Pabianice, PL); Michal Kowalski (Godziszka, PL); Piotr Niedziejko (Warsaw, PL); Sylwia Olejniczak (Lodz, PL); Krzysztof Matyszewski (Lodz, PL); Robert Koralewski (Lodz, PL); Jacek Olczak (Lodz, PL); Adam Golebiowski (Madison, CT); Agnieszka Bartoszewicz (Warsaw, PL)
Assignee: Molecure S.A.
A61K31/5365A61K31/454A61K31/4545A61K31/5355A61K45/06C07D401/14C07D413/14C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,638,707
App. No.
16/929,893
Granted
May 2, 2023
Kind
B2
Abstract

Disclosed are amino triazole compounds of formula (I). These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as well as acute and chronic inflammatory diseases, autoimmune diseases, dental diseases, neurologic diseases, metabolic diseases, liver diseases, polycystic ovary syndrome, endometriosis, and cancer.

Claims (18)

1. A compound represented by formula (I),

wherein:

W is Cl or Br; and

R 2 is fluoro(C 1 -C 6 )alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein W is chloro.

3. The compound of claim 1 , wherein R 2 is fluoro(C 1 -C 2 )alkyl.

4. The compound of claim 1 , wherein R 2 is fluoro(C 1 )alkyl.

5. The compound of claim 1 , wherein R 2 is fluoro(C 2 )alkyl.

6. The compound of claim 1 , wherein R 2 is —CH 2 F.

7. The compound of claim 1 , wherein R 2 is —CHF 2 .

8. The compound of claim 1 , wherein R 2 is —CF 3 .

9. The compound of claim 1 , wherein R 2 is —CH 2 CF 3 .

10. The compound of claim 1 , wherein R 2 is —CHFCH 3 .

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, represented by any one of the following structural formulae:

12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 ; and a pharmaceutically acceptable carrier.

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, represented by the following structure:

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, represented by the following structure:

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Feb 17, 2023
From: GILEAD SCIENCES, INC.
To: GALAPAGOS NV
Reel/Frame 062733/0145 →
CHANGE OF NAME Recorded Aug 4, 2022
From: ONCOARENDI THERAPEUTICS S.A.
To: MOLECURE S.A.
Reel/Frame 061072/0709 →
SECURITY INTEREST Recorded Feb 15, 2022
From: GALAPAGOS NV
To: GILEAD SCIENCES, INC
Reel/Frame 059020/0896 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2021
From: MAZUR, MARZENA; ANDRYIANAU, GLEB; JOACHIMIAK, LUKASZ; CZESTKOWSKI, WOJCIECH; KOWALSKI, MICHAL L.; NIEDZIEJKO, PIOTR; OLEJNICZAK, SYLWIA; MATYSZEWSKI, KRZYSZTOF; KORALEWSKI, ROBERT; OLCZAK, JACEK P.; GOLEBIOWSKI, ADAM A.; BARTOSZEWICZ, AGNIESZKA
To: ONCOARENDI THERAPEUTICS S.A.
Reel/Frame 055059/0978 →
Priority Claims (1)
PL 430586 · Jul 15, 2019 · national
Continuity (2)
Provisional Application 62874108 · Jul 15, 2019
Related Publication 20210015822A1 · Jan 21, 2021